The Annual Vaccines + Therapeutics Summit is dedicated to the future in the war against bioterrorism, infectious disease threats and antimicrobial resistance and the importance of innovation in fighting back.
The Annual Vaccines + Therapeutics Summit covers topics such as:
EMERGING INFECTIOUS DISEASES: What R&D and rapid response efforts need to take place to prevent diseases such as MERS, Q-Fever, Flu, NDM-1, Zika Virus, and TB? Will there be a greater prioritization for investing towards the prevention of EIDs?
ANTIMICROBIAL RESISTANCE: The failure to tackle drug-resistant infections is expected to cost the global economy up to $100 trillion by 2050. The federal government created a $1.2 billion investment towards the funding for antibiotic resistance for FY 2016. How will funding be distributed?
BIODEFENSE: A report by the Blue Ribbon Study Panel says the US is not prepared to deal with a biological event. How will funding be reinvigorated? How will public-private partnerships transform?
The Annual Vaccines + Therapeutics Summit brings together government, private companies and other stakeholders from the U.S. and the rest of the world.